ABBV Stock Summary and Trading Ideas (Abbvie | NYSE:ABBV)

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Abbvie trades on the NYSE stock market under the symbol ABBV.

As of April 2, 2026, ABBV stock price declined to $208.84 with 4,662,133 million shares trading.

ABBV has a beta of 0.42, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.08 to the broad based SPY ETF.

ABBV has a market cap of $369.39 billion. This is considered a Mega Cap stock.

Last quarter Abbvie reported $17 billion in Revenue and $2.71 earnings per share. This beat revenue expectation by $225 million and exceeded earnings estimates by $.05.

In the last 3 years, ABBV traded as high as $244.81 and as low as $130.96.

The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.

ABBV has underperformed the market in the last year with a return of +4.5%, while the SPY ETF gained +18.2%. In the last 3 month period, ABBV fell short of the market, returning -7.8%, while SPY returned -3.6%. However, in the most recent 2 weeks ABBV has outperformed the stock market by returning +0.2%, while SPY returned -0.6%.

ABBV support price is $210.99 and resistance is $218.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.